Breathe Well Live Well
Conditions: Pain; Trismus; Edema
Interventions: Drug: mepivacaine chloridrato epinephrine; Drug: mepivacaine chloridrato levonordefrin
Sponsor: University of Sao Paulo
Active, not recruiting – verified November 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
 |
Related Articles |
Effect of different helminth extracts on the development of asthma in mice: the influence of early-life exposure and the role of IL-10 response.
Exp Parasitol. 2015 Jun 17;
Authors: Pitrez PM, Gualdi LP, Barbosa GL, Sudbrack S, Ponzi D, Cao RG, Silva AC, Machado DC, Jones MH, Stein RT, Graeff-Teixeira C
Abstract
It is not currently clear whether different parasites have distinct effects on the airway inflammatory response in asthma and whether exposure in early life to helminths have a stronger impact in a potential inhibitory effect on asthma. The aim of this study is to evaluate the effect of exposure to different helminth extracts on the development of allergic pulmonary response in mice, including early-life exposure. Different helminth extracts (Angiostrongylus costaricensis, Angiostrongylus cantonensis and Ascaris lumbricoides) were studied in female adult BALB/c and C57BL/6 IL-10-deficient mice in a protocol of murine asthma, injected intraperitoneally in different periods of exposure (early, pre-sensitization and post-sensitization). Cell counts in bronchoalveolar lavage (BAL), eosinophil peroxidase (EPO) from lung tissue, cytokine levels from BAL/spleen cell cultures, and lung histology were analyzed. Airway cellular influx induced by OVA was significantly inhibited by extracts of A. cantonensis and A. lumbricoides. Extracts of A. lumbricoides and A. costaricensis led to a significant reduction of IL-5 in BAL (p<0.001). Only the exposure to A. lumbricoides led to an increased production of IL-10 in the lungs (p<0.001). In IL-10-deficient mice exposed to A. costaricensis pre-sensitization, eosinophil counts and IL-5 levels in BAL and EPO in lung tissue were significantly reduced. In the early exposure to A. cantonensis, lung inflammation was clearly inhibited. In conclusion, different helminth extracts inhibit allergic lung inflammation in mice. IL-10 may not play a central role in some helminth-host interactions. Early exposure to helminth extracts could be a potential strategy to explore primary prevention in asthma.
PMID: 26093162 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Effect of Common Comparators in Indirect Comparison Analysis of the Effectiveness of Different Inhaled Corticosteroids in the Treatment of Asthma.
PLoS One. 2015;10(3):e0120836
Authors: Kunitomi T, Hashiguchi M, Mochizuki M
Abstract
PURPOSE: Indirect comparison (IC) and direct comparison (DC) of four inhaled corticosteroid (CS) treatments for asthma were conducted, and the factors that may influence the results of IC were investigated. Among those factors, we focused on the effect of common comparator selection in the treatment of asthma, where little control group bias or placebo effect is expected.
METHOD: IC and DC were conducted using the change from baseline in forced expiratory volume in 1 s (FEV1(L)) as an outcome parameter. Differences between inhaled CS were evaluated to compare the results of IC and DC. As a common comparator for IC, placebo (PLB) or mometasone (MOM) was selected. Whether the results of IC are affected by the selection of a common comparator and whether the results of IC and DC are consistent were examined.
RESULTS: 23 articles were identified by a literature search. Our results showed that ICs yielded results similar to DCs in the change from baseline of FEV1(L). No statistically significant difference was observed in inconsistency analysis between ICs and DCs. It was clinically and statistically confirmed that ICs with PLB and those with MOM did not differ in terms of the results of FEV1(L) analysis in this dataset.
CONCLUSION: This study demonstrated that ICs among inhaled CS can deliver results consistent with those of DCs when using the change from baseline in FEV1(L) as an outcome parameter in asthma patients. It was also shown that using an active comparator has similar results if there is no effect of control group bias. It should be emphasized that the investigation of control group bias is a key factor in conducting relevant ICs so that an appropriate common comparator can be selected.
PMID: 25793900 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
EmpowHer |
COPD and Asthma Aren't the Same: Here's What's Different
EmpowHer Chronic obstructive pulmonary disease (COPD) and asthma are both conditions that cause coughing, wheezing and shortness of breath. Although it is easy to confuse them, it is important to know which condition you have so you can get the most effective … |
View full post on asthma – Google News
Lung Disease News |
Asthma and COPD Have Similar Symptoms, Different Treatments
Lung Disease News asthma and COPD A seasoned allergist and fellow from the American College of Allergy, Asthma and Immunology (ACAAI) recently presented a study during the institution's Annual Scientific Meeting on the overlapping symptoms of chronic obstructive … |
View full post on asthma – Google News
|
Asthma vs. COPD, similar symptoms — Different causes and treatment
EurekAlert (press release) ATLANTA, GA (November 7, 2014) – Coughing, wheezing and shortness of breath are symptoms asthma sufferers are used to. They are also the symptoms of chronic obstructive pulmonary disease (COPD). For sufferers, as well as physicians, it can be difficult … Mouse Infestations Cause More Asthma Symptoms than Cockroach Exposure |
View full post on asthma – Google News
Medical News Today |
Asthma vs. COPD, Similar Symptoms – Different Causes and Treatment
Newswise (press release) Newswise — ATLANTA, GA (November 7, 2014) – Coughing, wheezing and shortness of breath are symptoms asthma sufferers are used to. They are also the symptoms of chronic obstructive pulmonary disease (COPD). For sufferers, as well as physicians, … How does stigma surrounding COPD affect research and care? |
View full post on asthma – Google News
Condition: Asthma
Interventions: Device: ELLIPTA; Device: DISKUS/ACCUHALER; Device: MDI; Device: TURBUHALER
Sponsor: GlaxoSmithKline
Not yet recruiting – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
| Related Articles |
Effect of Different Positions on FVC and FEV1 Measurements of Asthmatic Patients.
J Phys Ther Sci. 2014 Apr;26(4):591-3
Authors: Melam GR, Buragadda S, Alhusaini A, Alghamdi MA, Alghamdi MS, Kaushal P
Abstract
[Purpose] The purpose of our study was to investigate the effect of different positions on pulmonary function test (PFT) values such as forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) of asthmatic patients .[Subjects and Methods] Thirty subjects with severe asthma aged between 20-39 years were enrolled after they had signed a written consent. Subjects were selected using the inclusion criteria, and PFT were randomly administered. Spirometer measurements (FVC, FEV1) were taken in the supine, side lying on right, side lying on left, sitting and standing positions. Each measurement was taken three times, and the average values were analyzed. [Results] One- way analysis of variance (ANOVA) and Tukey’s Test (post hoc) for pair- wise comparison indicated that there was a significant difference in the FEV1 values of the asthmatic patients however a significant difference was obtained between standing and supine positions. There was also a significant difference in the FVC values between the standing and supine lying position in the pair -wise comparison. [Conclusion] This study showed standing is the best position for measuring FEV1 and FVC of asthmatic subjects. The more upright the position, the higher the FEV1 and FVC will be.
PMID: 24764640 [PubMed]
View full post on pubmed: asthma
Condition: Asthma
Interventions: Drug: Indacaterol 27.5 mcg; Drug: Indacaterol 37.5; Drug: Indacaterol 55 mcg; Drug: Indacaterol 75 mcg; Drug: Indacaterol 150 mcg; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified October 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days